Advertisement

Topics

AMEVIVE Company Profile

10:39 EST 14th December 2018 | BioPortfolio

AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a prescription medication that is injected by your doctor (15 mg IM, into the muscle) once a week for a total of 12 doses.

Location

14 Cambridge Center
Cambridge
Massachusetts
02142
United States of America

Contact

Phone: 1-866-263-8483
Email: webmaster@us.astellas.com


News Articles [0 Results]

None

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Amevive [Astellas Pharma US Inc.]

AMEVIVE (alefacept)These highlights do not include all the information needed to use AMEVIVE safely and effectively. See full prescribing information for AMEVIVE. AMEVIVE (alefacept), for injection, f...

PubMed Articles [0 Results]

None

Clinical Trials [11 Associated Clinical Trials listed on BioPortfolio]

AMEVIVE® Pregnancy Registry

This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant s...

Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients

An open-label, multicentre study to evaluate the efficacy and safety of one course of weekly intramuscular administration of Amevive in Taiwan patients with chronic plaque psoriasis

Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis

The purpose of this research study is to see how well the medication Alefacept (Amevive®) works for continuous treatment of chronic plaque psoriasis. The US Food and Drug Administration ...

Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis

The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psor...

A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

The purpose of this study is to find out how safe and effective an investigational drug called alefacept (amevive) is for the treatment of moderate to severe erosive mucosal lichen planus....

Companies [1 Associated Companies listed on BioPortfolio]

AMEVIVE

AMEVIVE is the first biologic approved by the FDA for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AMEVIVE is a presc...

More Information about "AMEVIVE" on BioPortfolio

We have published hundreds of AMEVIVE news stories on BioPortfolio along with dozens of AMEVIVE Clinical Trials and PubMed Articles about AMEVIVE for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AMEVIVE Companies in our database. You can also find out about relevant AMEVIVE Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...


Corporate Database Quicklinks



Searches Linking to this Company Record